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Phenytoin Sensitivity of Fibroblasts
as the Basis for Susceptibility to Gingival Enlargement
THOMAS M. HASSELL, DDS, Dr.med.dent., PhD, and
GREGG H. GILBERT, BS
A side effect of long-term administration of the anti-
epileptic drug phenytoin is overgrowth of the connec-
tive tissues surrounding the teeth. In this in vitro study
of protein and collagen synthesis by diploid fibroblasts
from 17 nonepileptic young persons with healthy gin-
givae, only seven strains of cells responded to pheny-
toin in culture medium. Because not all phenytoin-
APPROXIMATELY 40-50% of all persons treated
with the antiepileptic drug phenytoin (PHT; Dilan-
tin, Parke-Davis, Morris Plains, NJ; sodium 5,5-
diphenylhydantoinate) develop esthetically disfigur-
ing enlargement of the gingivae (Figure 1).1 The
lesion is characterized histologically by an accumula-
tion of connective tissue matrix within the gingiva
propria. "4 Although the pathogenesis involves sev-
eral factors (for a review, see Hassell'), there is
consensus that direct action of PHT upon resident
gingival fibroblasts is the primary factor determining
incidence of the lesion. Fibroblasts within normal
connective tissue appear similar at the light-micro-
scopic level; however, there exists a considerable
body of evidence indicating that such cells are func-
tionally different.5-7 Discrete and phenotypically
stable subpopulations of fibroblasts exist within gin-
giva and other connective tissues; these subpopula-
tions are characterized by dramatic differences in
protein synthesis, collagen production, glycosamino-
glycan accumulation, replicative life span in culture,
proliferation rate, cell size distribution and response
to exogenously added substances.5 '7-" PHT may
stimulate5 12'13 or inhibit 14-6 synthetic or proliferative
activity in cell subpopulations that are responsive to
the drug. It is possible that individuals who do not
develop gingival enlargement subsequent to PHT
therapy do not possess a genetically determined
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treated individuals develop gingival overgrowth, we
suggest that susceptibility is predicated upon the pres-
ence of a (genetically determined) phenytoin-sensitive
subpopulation of gingival fibroblasts. The concept of
the participation of sensitive cell subpopulations in
other connective tissue disorders is supported by these
findings. (Am J Pathol 1983, 112:218-223)
PHT-sensitive fibroblast subpopulation ("responder
cells"; Hassell et al.8).
The purpose of the present study was to determine
whether mass cultures of fibroblasts from clinically
healthy, nonepileptic young persons contained PHT-
sensitive cell subpopulations, as determined by
measuring protein and collagen synthesis in cells ex-
posed to PHT in vitro.
Materials and Methods
Subjects
Seventeen young persons volunteered to partici-
pate in the study. The experimental protocol was
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Figure 1 a-Clinical appearance of clinically normal human gin-
givae in a 20-year-old woman. Note the absence of signs of inflam-
mation. Sulcus Bleeding Index = 0; Plaque Index = 0. b-Clini-
cal appearance of grossly enlarged and overgrown human gingivae
in a 21-year-old male epileptic who had been taking phenytoin on a
daily regimen for 2 years. Note the fibrotic, lobular appearance and
the lack of inflammatory manifestations. (Courtesy of Dr. A. Ogilvie)
reviewed and approved by the University of North
Carolina Committee on Investigations Involving
Human Subjects. Each was given a thorough oral
prophylaxis by a dental hygienist and was instructed
to practice intensive oral hygiene for a 2-week period
to bring the level of gingival health to a maximum,
as evidenced by scores of 0 for the Plaque Index17
and Sulcus Bleeding Index"8 in the upper right pre-
molar region. All indexes were determined by one
clinician (T.M.H.).
Derivation of Fibroblasts and Cell Culture Methods
Anesthetic solution (Mepivacain HCl) containing
no vasoconstrictor was injected into the mucobuccal
fold area superior to the maxillary right premolar
teeth. A scalpel (Bard-Parker No. 11) was used from
the buccal approach to excise the tip of the healthy
interdental papilla between the two premolars. The
tissue was immediately minced with sterile scissors
and transferred to a Leighton tube in 2.0 ml of
Eagle's minimum essential medium (MEM, No.
410-1100, GIBCO, Grand Island, NY) supplemented
with sodium pyruvate (0.11 g/l), L-serine (10.5 mg/i),
L-asparagine (15 mg/i), L-glutamine (1.16 g/l), strep-
tomycin sulfate (100 mg/i), penicillin G (100,000
units/i), sodium bicarbonate (2.2 g/l), and 10% fetal
bovine serum (FBS). Henceforth in this paper, unless
otherwise noted, the abbreviation MEM refers to this
preparation. Incubation was at 37 C in an atmo-
sphere of 5% CO2-95% air, in 100% humidity. The
medium was changed twice a week by removing 1.0
ml and adding 1.0 ml of fresh MEM. Within 5 days,
fibroblasts began to emigrate from tissue fragments.
When the cells became confluent around most of the
tissue fragments, medium was removed and the cell
layer was rinsed twice with Hanks' buffered saline
(-CA++, Mg++); then 1.0 ml of 0.05'70 trypsin in EDTA
buffer was added and incubation continued for three
minutes to dislodge the cells, which were aspirated
from the Leighton tubes and placed into 25-sq cm
plastic flasks (No. 3012, Falcon Plastics, Oxnard,
Calif). When confluence was achieved, the cells were
transferred to a 75-sq cm flask (Falcon 3025), and
subsequently split one-to-three. After three such pas-
sages, the cells were stored in liquid nitrogen, in
sealed vials containing MEM plus 807o dimethylsulf-
oxide.
In the experiments described, approximately 1.5 x
106 cells of passage 3 to 7 were thawed, seeded into
75-sq cm flasks in MEM, and grown to early conflu-
ence. The cells were harvested, and an aliquot was
counted with the use of HIAC Particle Counter and
Sizer (Pacific Scientific Co., Menlo Park, Calif)
equipped with sensor CMH-90. Then equal numbers
(5-100 x 103) of each fibroblast strain were seeded in
0.5 ml of MEM into Linbro test wells (Flow Labora-
tories, McLean, Va, No. 76-033-05 flat bottom) and
permitted to attach overnight. Medium was then
changed, and the cells were incubated for an addi-
tional 24 hours. Quadruplicate wells were prepared
for pulse labeling and for cell counting.
Exposure of Cells to PHT
Culture medium containing PHT (5 ,Ag/ml) was
prepared by dissolving 10 mg of PHT-sodium (Sigma
Chemical Co., St. Louis, Mo) in 1.0 ml of a vehicle
consisting of a 1:1:1 vol/vol ratio of absolute
ethanol, propylene glycol, and 0.01% NaOH (wt/vol
with double-distilled water). Ten microliters of this
stock solution were added to 20.0 ml of serum-free
MEM containing 50,Ag/ml sodium ascorbate. Thus,
the final concentration of the vehicle was 1:2000 ver-
sus medium. Control wells received the same medium
containing vehicle, but without PHT. Incubation was
continued for 24 hours. To ensure that the proper
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concentration of PHT was achieved in the medium,
gas-liquid chromatography of representative me-
diums was performed by the on-column methylation
technique of Dudley et al.19 The 5 Mig/ml PHT con-
centration was selected because this is the measured
drug concentration in overgrown gingiva20 and be-
cause neither the incidence nor the severity of the
lesion is dose-dependent.12'
Pulse Labeling, Cell Harvest, and Counting
All medium was removed and replaced with 0.5 ml
of the PHT-containing medium, to which L-3H-Pro-
line (New England Nuclear, Boston, Mass) had been
added to make 10 pICi/ml. The pulse was continued
for 25 hours. Wells intended for cell counting re-
ceived the same medium but without label; these were
harvested by trypsinization, and the total number of
cells per well was determined by the use of the HIAC
counter. Pulsed cells were harvested by removing the
0.5 ml of labeled medium to a dialysis casing, scrap-
ing the cell layer off in 1.0 ml of 0.1 N acetic acid with
a rubber policeman, adding the cells to the dialysis
casing and rinsing the well with an additional 0.5 ml
of acetic acid. Dialysis was performed 3 x 12 hours
versus cold double-distilled water and 3 x 12 hours
versus cold buffer solution (0.05 M Tris-HCl, 0.2 M
NaCl, 0.005 M CaCl2, pH 7.4). A 400-,ul aliquot of
the retentate was counted in 5.0 ml of Aquasol-2
(New England Nuclear) in a liquid scintillation spec-
trometer (Packard Tricarb). These counts indicated
nondialyzable radioactivity and were taken as a
measure of net synthetic activity and accumulation
during the 25-hour pulse period.
Estimation of Collagen Synthesis
Two hundred microliters of the dialyzed material
(see above) were reacted for 6 hours in a shaking
water bath (34 C) with about 25 units of chromato-
graphically purified bacterial collagenase (Form III,
Advance Biofactures, Lynbrook, NY; this prepara-
tion was free of nonspecific proteolytic activity) pre-
pared in a 0.025 M Tris-HCl, 0.33 M calcium acetate
buffer (pH 7.4) according to the manufacturer's
directions, in the presence of 1 mM N-ethylmalei-
mide (prepared in 0.05 M Tris-HCl, 0.02 M NaCl,
0.005 M CaCl2 buffer at pH 7.4).22 The reaction mix-
ture was then promptly cooled on ice, and 200 pl of
a 5Wo trichloroacetic acid-0.5Wo tannic acid solution
was added. Also, 25 pl of FBS was added to enhance
protein precipitation. The mixture was permitted to
stand at 4 C for 15 minutes, then centrifuged 10
minutes at 10,000g. Two hundred microliters of the
supernatant were counted in 5.0 ml of Aquasol-2,
and these data were reduced as described by Peter-
kofsky and Diegelmann22 to derive an accurate
assessment of collagen synthetic activity expressed as
collagenase-digestible protein.
Statistical Analysis
Data for PHT-treated cultures were compared
with those for control cultures by means of the
Student t test.
Table 1 -Total Synthetic Activity by 17 Strains of Human Gingival Fibroblasts




























































































* Reported as cpm x 10-3 per 106 cells (± SD) for quadruplicate determinations.
t Not significant at P < 0.05.
AJP * August 1983
FIBROBLAST RESPONSE TO PHENYTOIN 221
Table 2-Production of Collagenase-Digestible Protein by 17 Strains of Human Gingival Fibroblasts



















































































































































* Reported as cpm x 10-3 per 106 cells (+ SD) for quadruplicate de
t Expressed as collagenase-released cpm
(noncollagen protein cpm x f) + collagenase-relea
Results
Large interstrain differences in the magnitude of
protein and collagen synthesis were observed. Seven
of the 17 strains of normal human gingival fibro-
blasts exhibited sensitivity to PHT (Strains 1, 3, 8,
9, 12, 14, and 17). Total protein synthetic activity by
all 17 strains of cells is presented in Table 1, with data
expressed as counts per minute (cpm) per 106 cells. In
three of the 17 strains of cells, PHT elicited a sig-
nificant increase in protein synthesis. In two strains,
there was decreased synthesis associated with PHT
exposure. Total protein synthesis by the other fibro-
blast strains was not significantly affected either posi-
tively or negatively by PHT at this concentration.
Table 2 presents data concerning collagen syn-
thesis, expressed as cpm collagenase-digestible ma-
terial. Five strains exhibited sensitivity to PHT:
three strains synthesized elevated amounts of col-
lagen, while two exhibited decreased collagen pro-
duction in the presence of PHT. These observations
were statistically significant. In the other fibroblast
strains, no significant positive or negative effects of
PHT on collagen synthesis were observed.
The percentage of total cellular synthetic activity
dedicated to the production of collagen is also pre-
sented in Table 2, and ranged from 1.207o to 7.4'/o in
control cultures and from 1.3% to 5.907o in PHT-
treated cultures. These values are within the normally
expected range under our experimental conditions6.23
with the proline correction factor of 5.4 as suggested
by Peterkofsky and Diegelmann.22 In all strains
x 100, where f = 5.4 (Peterkofsky and Diegelmann22).
where collagen production was significantly increased
by PHT treatment (Strains 1, 8, and 9) the collagen/
protein value was elevated (by 10.7-32.7%, Table 2).
In the two strains where collagen production was de-
creased (Strains 14 and 17), the collagen/protein
value was negligibly influenced. Only in Strain 3 was
the percentage of collagen per protein dramatically
reduced (- 34%), and this in tandem with significant-
ly elevated total protein synthetic activity.
Discussion
The results of the present study suggest that not all
individuals harbor gingival fibroblasts with the
capacity to respond in vitro to the addition of PHT,
as manifested by changes in protein or collagen syn-
thetic activity. In view of the fact that only about
40-5007o of all PHT-treated individuals develop gin-
gival overgrowth,1 we suggest that susceptibility to
development of the lesion is predicated upon the
presence, within the gingival connective tissues, of a
subpopulation(s) of fibroblasts capable of respond-
ing to PHT (or to one of its metabolites24-26).
Other investigators have studied the effects of PHT
upon in vitro cellular synthetic activities. The data
have been inconsistent and contradictory. For ex-
ample, Kasai and Hachimine12 reported increases in
in vitro collagen synthesis by feline and human gin-
gival cells of 66-8407o after exposure to PHT at 1-5
pg/ml. On the other hand, Houck et al2' detected no
increase in collagen production by human (skin)
Vol. 112 * No. 2
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fibroblasts when PHT was added at 2-20,g/ml. Col-
lagen synthesis was decreased'5 in cultured 10-day-
old chick embryo tibia exposed to PHT at 40-2000
,xg/ml, as a result, according to Liu and Bhatnagar,16
of inhibition of the enzyme protocollagen proline
hydroxylase. However, no such inhibition of col-
lagen proline hydroxylation could be detected in in
vitro studies of human gingival fibroblasts.8'28
That PHT may stimulate or inhibit protein and
collagen synthesis has also been demonstrated in
whole animal studies. Kasai et al29 measured hydrox-
yproline levels in gingiva of PHT-treated rats and
found it to be 5 times higher than in nontreated rats,
indicating increased collagen content. Bazin and
Delaunay30 reported that PHT increased the rate of
collagen synthesis in rats, and also augmented col-
lagen polymerization ("maturation") as evidenced by
an increase in stable intermolecular cross-links. In a
guinea pig model, PHT at 40-80 mg/kg/day in-
creased the concentration of neutral-soluble and
acid-soluble collagen in granulomatous tissue.31
Phenytoin-induced increases in collagen synthesis
and accumulation have also been demonstrated in
several wound-healing studies in experimental ani-
mals and in man.32-34 Kusek35 reported decreased
protein synthetic rates in tissues of rats given PHT
(100 mg/kg) for 16 days.
A recurring observation in all of the in vitro and in
vivo studies cited is that not all cell strains in culture
responded to the addition of PHT, not all animals
treated with PHT exhibited connective tissue altera-
tions, and not all human subjects responded to PHT
by increased rate of wound healing. Similarly, in not
all persons with epilepsy who ingest PHT on a
chronic regimen does gingival overgrowth develop.
Response or nonresponse to the drug is an individual
phenomenon. On the basis of our current finding that
not all normal human gingivae contain PHT-sensi-
tive fibroblasts, we suggest that this individuality of
response to the effects of PHT on connective tissue is
due to the presence or absence, within an individual,
of a PHT-sensitive population of fibroblasts. The
sensitivity may relate to an individual cell's ability to
bind PHTs 36 or to its ability to metabolize the drug
effectively.7'3'
In a broad sense, the present study emphasizes the
cellular biochemical heterogeneity underlying PHT-
induced gingival overgrowth. That such heterogene-
ity may play a role in the etiology of gingival and
other connective tissue diseases is a relatively new
concept, an alternative to the cell-injury model. Fi-
broblast subpopulations with genetically determined
sensitivity to a wide range of putatively pathogenic
endogenous and exogenous substances may represent
a crucial factor in the incidence and severity of a va-
riety of connective tissue diseases in susceptible in-
dividuals, while the absence of such subpopulations
may determine a measure of disease resistance.
In summary, of the 17 different strains of normal
human gingival fibroblasts studied, 7 responded in
vitro to the addition of PHT to the culture medium.
Both enhancement and inhibition of synthetic activi-
ty were observed. The other 10 cell strains were
neither positively nor negatively affected by PHT.
We propose that susceptibility to PHT-induced gin-
gival enlargement may hinge upon the presence or
absence of a genetically determined and stable sub-
population of PHT-sensitive resident gingival fibro-
blasts. Subpopulations of fibroblasts sensitive to
other putatively etiologic agents may be of patho-
genetic significance in other connective tissue dis-
orders with more clinical significance.
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